Abatacept inhibits inflammation and onset of rheumatoid arthritis in individuals at high risk (ARIAA): a randomised, international, multicentre, double-blind, placebo-controlled trialJürgen Rech, Georg Schett, Uta Kiltz et al.|The Lancet|2024Cited by 134
Accuracy, patient-perceived usability, and acceptance of two symptom checkers (Ada and Rheport) in rheumatology: interim results from a randomized controlled crossover trialJohannes Knitza, Martin Welcker, Harriet Morf et al.|Arthritis Research & Therapy|2021Cited by 73
Treatment tapering and stopping in patients with rheumatoid arthritis in stable remission (RETRO): a multicentre, randomised, controlled, open-label, phase 3 trialKoray Taşçılar, Jürgen Rech, Karin Manger et al.|The Lancet Rheumatology|2021Cited by 31
IgA anti-citrullinated protein antibodies are associated with flares during DMARD tapering in rheumatoid arthritisMaria Sokolova, Jörg Henes, Karin Manger et al.|Lara D. Veeken|2021Cited by 17
Cost-effective Tapering Algorithm in Patients with Rheumatoid Arthritis: Combination of Multibiomarker Disease Activity Score and Autoantibody StatusMelanie Hagen, Jürgen Rech, Jayme Fogagnolo Cobra et al.|The Journal of Rheumatology|2018Cited by 11